Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 1.09 a new company low.

Within Biotechnology & Pharmaceuticals industry 129 other companies have achieved higher Quick Ratio than Genfit S A in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 881 to 1765.

Explain Quick Ratio?
How much Cash & cash equivalents GNFT�s has?
What are GNFT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GNFT Quick Ratio	(Dec 31 2024) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	95.33 %	95.33 %	95.33 %	95.33 %	-2.26 %
Y / Y Cash & cash equivalent Change	5.14 %	5.14 %	5.14 %	5.14 %	-42.8 %
Quick Ratio MRQ	1.09	1.09	1.09	1.09	2.02
GNFT's Total Ranking	# 1765	# 881	#	#	#
Seq. Current Liabilities Change	0 %	0 %	0 %	95.33 %	0 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	5.14 %	0 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 130
Healthcare Sector	# 669
Overall Market	# 1765

Quick Ratio Statistics
High	Average	Low
6.34	3.75	1.09
(Dec 31 2019)		(Dec 31 2024)

Financial Statements
Genfit S A 's Current Liabilities	$ 84 Millions	Visit GNFT's Balance sheet
Genfit S A 's Cash & cash equivalent	$ 92 Millions	Visit GNFT's Balance sheet
Source of GNFT's Sales		Visit GNFT's Sales by Geography

Cumulative Genfit S A 's Quick Ratio

GNFT's Quick Ratio for the trailling 12 Months

GNFT Quick Ratio	(Dec 31 2024) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	95.33 %	70.51 %	45.98 %	21.72 %	-2.26 %
Y / Y Cash & cash equivalent TTM Growth	5.14 %	-12.51 %	-25.36 %	-23.98 %	-34.19 %
Quick Ratio TTM	1.09	1.22	1.4	1.65	2.02
Total Ranking TTM	# 4031	# 3839	#	#	#
Seq. Current Liabilities TTM Growth	13.9 %	16.14 %	19.25 %	23.83 %	-0.57 %
Seq. Cash & cash equivalent TTM Growth	1.24 %	1.25 %	1.27 %	1.29 %	-15.76 %

Quick ratio ranking by company, industry and sector >> Back to GNFT Financial Strength Comparisons >> Go to Compare GNFT Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2024 to $84.18 millions, cumulative Quick Ratio decreased to 1.09 below the Genfit S A average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 160 other companies have achieved higher Quick Ratio than Genfit S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 3839 to 4031.

Explain Quick Ratio?
How much Cash & cash equivalents GNFT�s has?
What are GNFT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 161
Healthcare Sector	# 996
Within the Market	# 4031

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.34	3.73	1.09
(Dec 31 2019)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Leonabio Inc	2.97	$ 51.275 Millions	$ 17.256 Millions
Iovance Biotherapeutics inc	2.96	$ 323.781 Millions	$ 109.445 Millions
Inmune Bio Inc	2.90	$ 20.922 Millions	$ 7.221 Millions
Moderna Inc	2.87	$ 7,025.000 Millions	$ 2,446.000 Millions
Vigil Neuroscience Inc	2.86	$ 97.795 Millions	$ 34.147 Millions
Exelixis Inc	2.75	$ 1,111.276 Millions	$ 403.769 Millions
Candel Therapeutics Inc	2.74	$ 102.654 Millions	$ 37.529 Millions
Ocugen Inc	2.71	$ 58.514 Millions	$ 21.588 Millions
Sab Biotherapeutics Inc	2.60	$ 20.761 Millions	$ 7.980 Millions
Enzo Biochem Inc	2.46	$ 40.297 Millions	$ 16.359 Millions
Relay Therapeutics Inc	2.45	$ 124.287 Millions	$ 50.729 Millions
Sutro Biopharma Inc	2.40	$ 316.895 Millions	$ 131.893 Millions
Adaptimmune Therapeutics Plc	2.35	$ 151.605 Millions	$ 64.527 Millions
Vericel Corporation	2.31	$ 116.213 Millions	$ 50.286 Millions
Regenxbio Inc	2.27	$ 234.687 Millions	$ 103.194 Millions
Adaptive Biotechnologies Corporation	2.27	$ 222.294 Millions	$ 98.053 Millions
Humacyte Inc	2.25	$ 44.937 Millions	$ 19.954 Millions
Cognition Therapeutics inc	2.24	$ 25.009 Millions	$ 11.142 Millions
Monte Rosa Therapeutics Inc	2.12	$ 372.149 Millions	$ 175.731 Millions
Biomx Inc	2.04	$ 16.856 Millions	$ 8.267 Millions
Innate Pharma Sa	2.01	$ 74.364 Millions	$ 36.940 Millions
Biocryst Pharmaceuticals Inc	2.00	$ 321.060 Millions	$ 160.384 Millions
Lenz Therapeutics Inc	1.94	$ 20.158 Millions	$ 10.406 Millions
Adma Biologics Inc	1.90	$ 103.147 Millions	$ 54.181 Millions
Meiragtx Holdings Plc	1.71	$ 103.659 Millions	$ 60.783 Millions
Immunitybio inc	1.69	$ 149.809 Millions	$ 88.799 Millions
Vivosim Labs Inc	1.56	$ 2.901 Millions	$ 1.860 Millions
Beam Therapeutics Inc	1.55	$ 281.967 Millions	$ 182.066 Millions
Neurocrine Biosciences Inc	1.54	$ 1,076.100 Millions	$ 697.500 Millions
Intensity Therapeutics Inc	1.51	$ 2.600 Millions	$ 1.727 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.